Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026

Jan 26, 2016, 09:00 ET from Visiongain

LONDON, January 26, 2016 /PRNewswire/ --

Prospects for Technologies Including Trivalent and Quadrivalent Flu Shots

Influenza Vaccines - Your 2016 Guide to Developments and Sales Potentials
Do you want to explore the future of vaccines against the influenza virus? If so, visiongain's new report shows you trends, R&D, sales results, opportunities and revenue forecasts.

Avoid missing out. With our research and analysis you assess companies, technologies and products, benefiting your reputation for commercial insight.

Read on to explore the flu shots industry and see what revenue its market could generate in future.

Sales prospects of human flu preventions - our study shows you what is possible
Our new study gives revenue predictions at overall world, submarket, product and national levels. You gain discussions and expert opinion on vaccines protecting against influenza:
• Influenza vaccine revenues to 2026 - discover the overall potential of that market worldwide, seeing commercial opportunities and possibilities
• 2 submarkets' revenues to 2026 - explore that industry's segments at world level, finding the most lucrative and promising technologies and trends
• 6 revenue forecasts covering leading vaccine brands to 2026 - see how those anti-flu agents can compete and succeed, discovering their sales potentials
• 11 leading countries' revenue forecasts to 2026 - investigate countries in the Americas, Europe and Asia, assessing prospects for influenza market expansion
• Analysis of leading companies and R&D pipelines for that preventive medicine - assess potentials of companies, seeing how they can compete and succeed
• Assessment of what stimulates and restrains that important healthcare market - analyse challenges, strengths and views, seeing how you can gain.

Forecasting of that world market, showing what is possible for those prophylactic medicines
In our 138 page report you receive 32 tables, 32 charts and an interview with a vaccine producer. Besides giving revenue predictions, our new analysis shows you recent results, business news, sales growth rates, market shares and R&D trends.

First our study gives revenue forecasts to 2026 for two influenza submarkets:
• Trivalent vaccines
• Quadrivalent vaccines.

To see a report overview please email Sara Peerun on

With our report you investigate influenza vaccine development, manufacturing and selling. You also explore potential shifts in market shares from 2016 to 2026. See what leading companies do, assessing that industry's potential.

Product forecasts - assess sales potentials of leading brands
Our new analysis also shows you predictions for leading flu vaccines, giving six revenue forecasts to 2026:
• Fluzone/Vaxigrip
• Afluria/Fluvax
• Fluarix/FluLaval
• FluMist/Fluenz
• Fluvirin/Flucelvax
• FluBlok.

With our investigation you assess business potentials for leading influenza vaccines. You also explore research and development. Discover what is possible from 2016, then, benefiting your influence and reputation for commercial insight.

National markets for influenza vaccine sales - what does the future hold?
Our study shows you prospects for influenza vaccine revenues in developed and developing countries. There see individual forecasts to 2026 for 11 countries:
United States
Germany, France, United Kingdom, Italy and Spain (the EU5 group)
Brazil, Russia, India and China (the BRIC group).

With our analysis you investigate countries with highest revenues, demand and potential sales growth. Explore progress, needs and opportunities, seeing how you can gain.

Forces affecting developers, producers and sellers of those healthcare products
Our report explains issues, trends, events and R&D from 2016, including these forces:
• Paediatric and adult influenza vaccines - present and future developments
• Advances in research and development, including vaccine delivery technology - assess innovations, progress and opportunities
• Deals in that industry, including the creation of Seqirus in July 2015
• Antigenic drift and shift - overcoming viral challenges to protect populations
• Seasonal influenza epidemics and pandemic outbreaks giving high demand.

Also explore the effects of these influences:
• Governments and international organisations' roles in flu vaccination
• Supply and demand, including effects of healthcare providers and payers' policies
• US healthcare reforms - benefits for vaccine sales
• Strengths, weaknesses, opportunities and threats, as well as social, technological, economic and political forces - examine what influences that industry
• Potential for universal flu vaccine to transform the market - see what is possible.

Worldwide revenues of influenza vaccines will reach $6.4 billion in 2018, our study predicts. Sales will rise from 2016 to 2026 as technological advances and rising demand give growth opportunities. With our analysis you see what the future holds and how you can benefit.

Influenza vaccines - who are the top companies?
From 2016, large pharmaceutical companies and other biopharma specialists can prosper in that important healthcare market. Discover how, seeing organisations' potentials.

In particular our study explores these industry leaders:
• Sanofi Pasteur
• Novartis
• AstraZeneca
• CSL and Seqirus
• Protein Sciences Corporation.

Gain predictions for influenza vaccines, getting information to help you stay ahead
With our independent study you assess products, companies, progress and potentials. Explore commercial opportunities and technological advances. Discover what is possible.

Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.

Try our new study. That investigation shows you data, trends, opportunities and forecasts for that expanding vaccine market. So avoid missing out - please get our report here now.

To see a report overview please email Sara Peerun on

To request an exec summary of this report please email Sara Peerun at or call Tel: +44(0)20-7336-6100

Or click on

Companies and Other Organisations Mentioned 

Advisory Committee for Immunization Practices

Astellas Pharmaceuticals


Bharat Immunologicals and Biologicals Corporation Limited



BioManguinhos/Oswaldo Cruz Foundation




Brazilian Ministry of Health

Butantan Institute

Center for Biologics Evaluation and Research

Centre for Disease Control and Prevention

China National Biotech Group

China's National Regulatory Authority

Chinese Food and Drug Administration



Daiichi Sankyo


Flanders Institute

Food and Drug Administration (FDA)


Fresenius Pharmaceuticals

Gamma Vaccines

Gavi Alliance

GlaxoSmithKline (GSK)

Global Influenza Programme


Health Service Bureau, Japan

Immune Targeting Systems

Indian Association of Paediatrics

Janssen Pharmaceuticals

Jenner Institute, University of Oxford

Johnson & Johnson

Krka Pharmaceuticals





MSD Pharmaceuticals

National Health Service, UK


Organisation for Economic Co-operation and Development

Panacea Biotech

Partnership for Influenza Vaccine Introduction



Protein Sciences Corporation

Sanofi Pasteur


Servizio Sanitario Nationale

Shionogi Pharmaceuticals

Sistema Unico de Saude

SmithKline Beecham

Takeda Pharmaceuticals

Terumo Pharmaceuticals

The Ministry of Health, Labour and Welfare, Japan

The Scripps Research Institute


US Department of Health and Human Services


WHO Strategic Advisory Group of Experts

World Health Organization (WHO)

To see a report overview please email Sara Peerun on

SOURCE Visiongain